 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- JNJ-4703 / J&J
Efficacy, Safety, and Tolerability of JNJ-67484703 in Adult Patients With Moderate to Severe Atopic Dermatitis: Design of a Phase 2a Study (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2488;
P2
The RESTORE-AD phase 2 study will evaluate the efficacy, safety, and tolerability of JNJ-67484703 in adults with moderate and severe AD, using multiple clinical outcome measures.
- || JNJ-4703 / J&J
Trial completion: A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 29, 2023
P1, N=44, Completed, Sponsor: Janssen Research & Development, LLC
The RESTORE-AD phase 2 study will evaluate the efficacy, safety, and tolerability of JNJ-67484703 in adults with moderate and severe AD, using multiple clinical outcome measures. Active, not recruiting --> Completed
- || JNJ-4703 / J&J
Enrollment closed: A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Apr 13, 2023
P1, N=44, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | JNJ-4703 / J&J
Trial primary completion date: A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 16, 2023
P1, N=47, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2022 --> May 2023
- |||| JNJ-4703 / J&J
New P2 trial: A Study of JNJ-67484703 in the Treatment of Participants with Moderate to Severe Atopic Dermatitis (EUDRACT) - Feb 9, 2023
P2, N=51, Ongoing, Sponsor: Janssen-Cilag International NV
- || JNJ-4703 / J&J
Enrollment open: A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Oct 27, 2021
P1, N=42, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2022 --> May 2023 Not yet recruiting --> Recruiting
- | JNJ-4703 / J&J
Trial completion date: A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 1, 2021
P1, N=42, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial completion date: Sep 2023 --> Apr 2023
- | JNJ-4703 / J&J
Trial completion date: A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 18, 2021
P1, N=42, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Sep 2023 --> Apr 2023 Trial completion date: Apr 2023 --> Sep 2023
- || JNJ-4703 / J&J
New P1 trial: A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 1, 2021
P1, N=42, Not yet recruiting, Sponsor: Janssen Research & Development, LLC